Claims for Patent: 5,942,496

Summary for Patent: 5,942,496

Title:	Methods and compositions for multiple gene transfer into bone cells
Abstract:	Disclosed are methods, compositions, kits and devices for use in transferring nucleic acids into bone cells in situ and/or for stimulating bone progenitor cells. Type II collagen and, particularly, osteotropic genes, are shown to stimulate bone progenitor cells and to promote bone growth, repair and regeneration in vivo. Gene transfer protocols are disclosed for use in transferring various nucleic acid materials into bone, as may be used in treating various bone-related diseases and defects including fractures, osteoporosis, osteogenesis imperfecta and in connection with bone implants.
Inventor(s):	Bonadio; Jeffrey (Ann Harbor, MI), Goldstein; Steven A. (Ann Harbor, MI)
Assignee:	The Regent of The University of Michigan (Ann Arbor, MI)
Application Number:	08/316,650
Patent Claims:	1. A method for transferring nucleic acid segments into bone progenitor cells located within a bone progenitor tissue site of an animal, comprising contacting said tissue site with a composition comprising two or more nucleic acid segments and a structural bone-compatible matrix, so as to transfer said two or more nucleic acid segments into said cells, wherein said cells express transcriptional or translational products encoded by said nucleic acid segments. 2. The method of claim 1, comprising contacting bone progenitor cells with a composition comprising two nucleic acid segments and a structural bone-compatible matrix. 3. The method of claim 1, comprising contacting bone progenitor cells with a composition comprising three nucleic acid segments and a structural bone-compatible matrix. 4. The method of claim 1, wherein the contacting process comprises bringing said two or more nucleic acid segments into contact with said structural bone-compatible matrix to form a matrix-nucleic acid segments composition and bringing said matrix-nucleic acid segments composition into contact with said tissue site. 5. The method of claim 4, wherein said nucleic acid segments are absorbed in said structural bone-compatible matrix. 6. The method of claim 4, wherein said nucleic acid segments are adsorbed to said structural bone-compatible matrix. 7. The method of claim 4, wherein said nucleic acid segments are impregnated within said structural bone-compatible matrix. 8. The method of claim 1, wherein said bone progenitor cells are stem cells, macrophages, fibroblasts, vascular cells, osteoblasts, chondroblasts or osteoclasts. 9. The method of claim 8, wherein said bone progenitor cells are fibroblasts. 10. The method of claim 1, wherein at least one of said two or more nucleic acid segments is a DNA molecule. 11. The method of claim 1, wherein at least one of said two or more nucleic acid segments is an antisense nucleic acid molecule. 12. The method of claim 1, wherein at least one of said two or more nucleic acid segments is a linear nucleic acid molecule, a plasmid or a recombinant insert within the genome of a recombinant virus. 13. The method of claim 1, wherein at least one of said two or more nucleic acid segments encodes a polypeptide or protein that stimulates bone progenitor cells when expressed by said cells. 14. The method of claim 1, wherein said structural bone-compatible matrix is a collagenous, metal, hydroxylapatite, bioglass, aluminate, bioceramic, acrylic ester polymer, lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 15. The method of claim 14, wherein said structural bone-compatible matrix is a titanium matrix. 16. The method of claim 15, wherein said structural bone-compatible matrix is a titanium matrix coated with hydroxylapatite. 17. The method of claim 14, wherein said structural bone-compatible matrix is a collagen preparation. 18. The method of claim 17, wherein said structural bone-compatible matrix is a type II collagen preparation. 19. The method of claim 18, wherein said structural bone-compatible matrix is a recombinant type II collagen preparation. 20. The method of claim 18, wherein said structural bone-compatible matrix is a type II collagen preparation further supplemented with minerals. 21. The method of claim 14, wherein said structural bone-compatible matrix is a lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 22. The method of claim 1, wherein at least one of said two or more nucleic acid segments is an RNA molecule. 23. A method of stimulating bone progenitor cells located within a bone progenitor tissue site of an animal, comprising contacting said tissue site with a composition comprising two or more osteotropic genes and a structural bone-compatible matrix so as to promote expression of said genes by said cells. 24. The method of claim 23, comprising contacting said tissue site with a composition comprising two osteotropic genes and a structural bone-compatible matrix. 25. The method of claim 23, comprising contacting said tissue site with a composition comprising three osteotropic genes and a structural bone-compatible matrix. 26. The method of claim 23, wherein expression of said osteotropic genes by said cells stimulates said cells to promote bone tissue growth. 27. The method of claim 23, wherein the contacting process comprises bringing said osteotropic genes into contact with said structural bone-compatible matrix to form a matrix-genes composition and bringing said matrix-genes composition into contact with said tissue site. 28. The method of claim 23, wherein said osteotropic genes are absorbed in said structural bone-compatible matrix. 29. The method of claim 23, wherein said osteotropic genes are adsorbed in said structural bone-compatible matrix. 30. The method of claim 23, wherein said osteotropic genes are impregnated within said structural bone-compatible matrix. 31. The method of claim 23, wherein said bone progenitor cells are stem cells, macrophages, fibroblasts, vascular cells, osteoblasts, chondroblasts or osteoclasts. 32. The method of claim 31, wherein said bone progenitor cells are fibroblasts. 33. The method of claim 23, wherein at least one of said two or more osteotropic genes is in the form of plasmid DNA, a DNA insert within the genome of a recombinant adenovirus, a DNA insert within the genome of a recombinant adeno-associated virus (AAV) or a DNA insert within the genome of a recombinant retrovirus. 34. The method of claim 23, wherein at least one of said two osteotropic genes is a parathyroid hormone (PTH) gene, a bone morphogenetic protein (BMP) gene, a growth factor gene, a growth factor receptor gene, a cytokine gene or a chemotactic factor gene. 35. The method of claim 34, wherein at least one of said two osteotropic genes is a PTH gene. 36. The method of claim 34, wherein at least one of said two osteotropic genes is a BMP-2A, BMP-2B, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7 or BMP-8 gene. 37. The method of claim 34, wherein at least one of said two osteotropic genes is a PTH1-34 gene, a BMP-2 gene or a BMP-4 gene. 38. The method of claim 34, wherein said composition comprises a PTH gene and a BMP gene. 39. The method of claim 38, wherein said composition comprises a PTH1-34 gene and a BMP-4 gene. 40. The method of claim 34, wherein at least one of said two osteotropic genes is a transforming growth factor (TGF) gene, a fibroblast growth factor (FGF) gene, a granulocyte/macrophage colony stimulating factor (GMCSF) gene, an epidermal growth factor (EGF) gene, a platelet derived growth factor (PDGF) gene, an insulin-like growth factor (IGF) gene, a latent TGF-.beta. binding protein (LTBP) gene or a leukemia inhibitory factor (LIF) gene. 41. The method of claim 40, wherein at least one of said two or more osteotropic genes is a TGF-.alpha., TGF-.beta.1 or TGF-.beta.2 gene. 42. The method of claim 40, wherein at least one of said two or more osteotropic genes is an LTBP gene. 43. The method of claim 22, wherein said structural bone-compatible matrix is a collagenous, metal, hydroxylapatite, bioglass, aluminate, bioceramic, acrylic ester polymer, lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 44. The method of claim 43, wherein said structural bone-compatible matrix is a titanium matrix. 45. The method of claim 44, wherein said structural bone-compatible matrix is a titanium matrix coated with hydroxylapatite. 46. The method of claim 43, wherein said structural bone-compatible matrix is a collagen preparation. 47. The method of claim 46, wherein said structural bone-compatible matrix is a type II collagen preparation. 48. The method of claim 47, wherein said structural bone-compatible matrix is a recombinant type II collagen preparation. 49. The method of claim 47, wherein said structural bone-compatible matrix is a mineralized type II collagen preparation. 50. The method of claim 43, wherein said structural bone-compatible matrix is a lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 51. The method of claim 23, wherein said composition is applied to a bone fracture site in said animal. 52. The method of claim 23, wherein said composition is implanted within a bone cavity site in said animal. 53. The method of claim 52, wherein said bone cavity site is the result of dental or periodontal surgery or the removal of an osteosarcoma. 54. A method of delivering two or more nucleic acid segments to a fibroblast cell located within a repair tissue site of an animal, comprising contacting said tissue site with a composition comprising two or more nucleic acid segments and a structural bone-compatible matrix to effect uptake of the nucleic acid segments into the fibroblast cell and to promote expression of transcriptional or translational products by said fibroblast cell. 55. A method of delivering two or more selected nucleic acid segments to a fibroblast cell located within a repair tissue site of an animal, comprising the steps of: (a) preparing a matrix-nucleic acid composition comprising two or more nucleic acid segments and a structural bone-compatible matrix; and (b) contacting said repair tissue site with the structural matrix-nucleic acid composition to effect uptake of the nucleic acid segments by the fibroblast cell, wherein said fibroblast cell expresses transcriptional or translational products encoded by said nucleic acid segments. 56. The method of claim 55, wherein step (a) comprises preparing a matrix-nucleic acid composition comprising two nucleic acid segments and a structural bone-compatible matrix. 57. The method of claim 55, wherein step (a) comprises preparing a matrix-nucleic acid composition comprising three nucleic acid segments and a structural bone-compatible matrix. 58. The method of claim 55, wherein said nucleic acid segments are absorbed in or adsorbed to said structural bone-compatible matrix. 59. The method of claim 55, wherein said nucleic acid segments are impregnated within said structural bone-compatible matrix. 60. The method of claim 55, wherein at least one of said two or more nucleic acid segments is a DNA molecule. 61. The method of claim 55, wherein at least one of said two or more nucleic acid segments is an RNA molecule. 62. The method of claim 55, wherein at least one of said two or more nucleic acid segments is an antisense nucleic acid molecule. 63. The method of claim 55, wherein at least one of said two or more nucleic acid segments is a linear nucleic acid molecule, a plasmid or a recombinant insert within the genome of a recombinant virus. 64. The method of claim 55, wherein at least one of said two or more nucleic acid segments is an osteotropic gene. 65. The method of claim 64, wherein at least one said osteotropic genes is a parathyroid hormone (PTH) gene, bone morphogenetic protein (BMP) gene, a growth factor gene, a growth factor receptor gene, a cytokine gene or a chemotactic factor gene. 66. The method of claim 65, wherein at least one of said osteotropic genes is a transforming growth factor (TGF) gene, a fibroblast growth factor (FGF) gene, a granulocyte/macrophage colony stimulating factor (GMCSF) gene, an epidermal growth factor (EGF) gene, a platelet derived growth factor (PDGF) gene, an insulin-like growth factor (IGF) gene, a latent TGF-.beta. binding protein (LTBP) gene or a leukemia inhibitory factor (LIF) gene. 67. The method of claim 66, wherein at least one of said osteotropic genes is a TGF-.alpha., TGF-.beta.1 or TGF-.beta.2 gene. 68. The method of claim 65, wherein at least one of said osteotropic genes is a PTH gene. 69. The method of claim 68, wherein at least one of said osteotropic genes is a PTH1-34 gene. 70. The method of claim 65, wherein at least one of said osteotropic genes is a BMP-2A, BMP-2B, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7 or BMP-8 gene. 71. The method of claim 70, wherein at least one of said osteotropic genes is a BMP-2 or BMP-4 gene. 72. The method of claim 65, wherein said matrix-nucleic acid composition comprises a PTH gene and a BMP gene. 73. The method of claim 72, wherein said matrix-nucleic acid composition comprises a PTH1-34 gene and a BMP-4 gene. 74. The method of claim 66, wherein at least one of said osteotropic genes is an LTBP gene. 75. The method of claim 55, wherein said structural bone-compatible matrix is a collagenous, metal, hydroxylapatite, hydroxylapatite-coated metal, bioglass, aluminate, bioceramic, acrylic ester polymer, lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 76. The method of claim 75, wherein said structural bone-compatible matrix is a titanium matrix. 77. The method of claim 76, wherein said structural bone-compatible matrix is a titanium matrix coated with hydroxylapatite. 78. The method of claim 75, wherein said structural bone-compatible matrix is a collagen preparation. 79. The method of claim 78, wherein said structural bone-compatible matrix is a type II collagen preparation. 80. The method of claim 79, wherein said structural bone-compatible matrix is a recombinant type II collagen preparation. 81. The method of claim 79, wherein said structural bone-compatible matrix is a type II collagen preparation further supplemented with minerals. 82. The method of claim 55, wherein said structural bone-compatible matrix is a lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 83. A composition comprising two or more nucleic acid segments in association with a structural bone-compatible matrix. 84. The composition of claim 83, wherein said composition comprises two nucleic acid segments in association with said structural bone-compatible matrix. 85. The composition of claim 83, wherein said composition comprises three nucleic acid segments in association with said structural bone-compatible matrix. 86. The composition of claim 83, wherein said nucleic acid segments are absorbed in or adsorbed to said structural bone-compatible matrix. 87. The composition of claim 83, wherein said nucleic acid segments are impregnated within said structural bone-compatible matrix. 88. The composition of claim 83, wherein at least one of said two or more nucleic acid segments is a DNA molecule. 89. The composition of claim 83, wherein at least one of said two or more nucleic acid segments is an RNA molecule. 90. The composition of claim 83, wherein at least one of said two or more nucleic acid segments is an antisense nucleic acid molecule. 91. The composition of claim 83, wherein at least one of said two or more nucleic acid segments is a linear nucleic acid molecule, a plasmid or a recombinant insert within the genome of a recombinant virus. 92. The composition of claim 83, wherein at least one of said two or more nucleic acid segments encodes a polypeptide or protein that stimulates bone progenitor cells when expressed by said cells. 93. The composition of claim 83, wherein said structural bone-compatible matrix is a collagenous, titanium, hydroxylapatite, hydroxylapatite-coated titanium, bioglass, aluminate, bioceramic, acrylic ester polymer, lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 94. The composition of claim 93, wherein said structural bone-compatible matrix is a collagen preparation. 95. The composition of claim 93, wherein said structural bone-compatible matrix is a type II collagen preparation. 96. The composition of claim 95, wherein said structural bone-compatible matrix is a recombinant type II collagen preparation. 97. The composition of claim 95, wherein said structural bone-compatible matrix is a type II collagen preparation further supplemented with minerals. 98. The composition of claim 97, wherein said structural bone-compatible matrix is a type II collagen preparation further supplemented with calcium. 99. The composition of claim 93, wherein said structural bone-compatible matrix is a lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 100. A composition comprising two or more osteotropic genes in association with a structural bone-compatible matrix, said composition being capable of stimulating bone growth when administered to a bone progenitor tissue site of an animal. 101. The composition of claim 100, wherein said composition comprises two osteotropic genes in association with said structural bone-compatible matrix. 102. The composition of claim 100, wherein said composition comprises three osteotropic genes in association with said structural bone-compatible matrix. 103. The composition of claim 100, wherein said osteotropic genes are absorbed in or adsorbed to said structural bone-compatible matrix. 104. The composition of claim 100, wherein said osteotropic genes are impregnated within said structural bone-compatible matrix. 105. The composition of claim 100, wherein at least one of said two or more osteotropic genes is in the form of plasmid DNA, a DNA insert within the genome of a recombinant adenovirus, a DNA insert within the geno of a recombinant adeno-associated virus (AAV) or a DNA insert within the genome of a recombinant retrovirus. 106. The composition of claim 100, wherein at least one of said two or more osteotropic genes is a PTH, BMP-2A, BMP-2B, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, TGF-.alpha., TGF-.beta.1, TGF-.beta.2, FGF, GMCSF, EGF, PDGF, IGF, LTBP or a LIF gene. 107. The composition of claim 106, wherein at least one of said osteotropic genes is a TGF-.alpha., TGF-.beta.1, TGF-.beta.2, PTH, LTBP, BMP-2 or BMP-4 gene. 108. The composition of claim 106, wherein at least one of said osteotropic genes is a PTH gene. 109. The composition of claim 108, wherein at least one of said osteotropic genes is a PTH1-34 gene. 110. The composition of claim 106, wherein at least one of said osteotropic genes is a BMP-2 or BMP-4 gene. 111. The composition of claim 106, wherein said composition comprises a PTH gene and a BMP gene. 112. The composition of claim 111, wherein said composition comprises a PTH1-34 gene and a BMP-4 gene. 113. The composition of claim 100, wherein said structural bone-compatible matrix is a collagenous, metal, hydroxyapatite, bioglass, aluminate, bioceramic, acrylic ester polymer, lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 114. The composition of claim 113, wherein said structural bone-compatible matrix is a titanium matrix. 115. The composition of claim 114, wherein said structural bone-compatible matrix is a titanium matrix coated with hydroxylapatite. 116. The composition of claim 113, wherein said structural bone-compatible matrix is a collagen preparation. 117. The composition of claim 116, wherein said structural bone-compatible matrix is a type II collagen preparation. 118. The composition of claim 117, wherein said structural bone-compatible matrix is a recombinant type II collagen preparation. 119. The composition of claim 117, wherein said structural bone-compatible matrix is a type II collagen preparation further supplemented with minerals. 120. The composition of claim 119, wherein said structural bone-compatible matrix is a type II collagen preparation further supplemented with calcium. 121. The composition of claim 113, wherein said structural bone-compatible matrix is a lactic acid polymer, glycolic acid polymer or lactic acid/glycolic acid polymer matrix. 122. An osteotropic device, comprising two or more osteotropic genes capable of expression by bone progenitor cells, the genes associated with an amount of a structural bone-compatible matrix effective to absorb or adsorb said genes, wherein said device is capable of stimulating bone formation when implanted within a bone progenitor tissue site of an animal. 123. The device of claim 122, wherein said device comprises three or more osteotropic genes. 124. The device of claim 122, wherein said device is a titanium or a hydroxylapatite-coated titanium device. 125. The device of claim 122, wherein said device is shaped to join a bone fracture site in said animal. 126. The device of claim 122, wherein said device is shaped to fill a bone cavity site in said animal. 127. The device of claim 122, wherein said device is an artificial joint. 128. The device of claim 122, wherein said device comprises a PTH, BMP-2A, BMP-2B, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, TGF-.alpha., TGF-.beta.1, TGF-.beta.2, FGF, GMCSF, EGF, PDGF, IGF, LTBP or a LIF gene. 129. The device of claim 128, wherein said device comprises a TGF-.alpha., TGF-.beta.1, TGF-.beta.2, PTH1-34, LTBP, BMP-2 or BMP-4 gene. 130. The device of claim 128, wherein said device comprises a PTH gene and a BMP gene.

Details for Patent 5,942,496

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2016-08-24